Is Calix a biotech stock? Today's Investor Presentation confirms that it is.
Set to become a multi-faceted conglomerate, Calix is claiming key territory in the hospital space - an ability to suppress golden staph and e-coli scourges by >90%.
A check of Slide 44 gives a glimpse of the group's plans. We're looking at a longer term strategy that may result in submissions to the FDA.
In the shorter term, discovery, development and possible partnering promises a steady, biotech-related news flow.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
-0.005(1.22%) |
Mkt cap ! $86.94M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 42.5¢ | 40.0¢ | $74.26K | 178.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15405 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 50818 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2025 (20 minute delay) ? |
| CXL (ASX) Chart |